SG10202101105XA - Charged depth filtration of antigen-binding proteins - Google Patents
Charged depth filtration of antigen-binding proteinsInfo
- Publication number
- SG10202101105XA SG10202101105XA SG10202101105XA SG10202101105XA SG10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- binding proteins
- depth filtration
- charged depth
- charged
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44791—Microapparatus
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562204831P | 2015-08-13 | 2015-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202101105XA true SG10202101105XA (en) | 2021-03-30 |
Family
ID=56802689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202101105XA SG10202101105XA (en) | 2015-08-13 | 2016-08-12 | Charged depth filtration of antigen-binding proteins |
Country Status (15)
Country | Link |
---|---|
US (2) | US11098079B2 (en) |
EP (2) | EP4209499A1 (en) |
JP (1) | JP6889149B2 (en) |
DK (1) | DK3334747T3 (en) |
ES (1) | ES2964640T3 (en) |
FI (1) | FI3334747T3 (en) |
HR (1) | HRP20231544T1 (en) |
HU (1) | HUE064252T2 (en) |
LT (1) | LT3334747T (en) |
MA (1) | MA42613A (en) |
PL (1) | PL3334747T3 (en) |
PT (1) | PT3334747T (en) |
SG (1) | SG10202101105XA (en) |
SI (1) | SI3334747T1 (en) |
WO (1) | WO2017027861A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
JP2020502218A (en) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ 3 リミテッド | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
CN107973487B (en) * | 2017-11-14 | 2021-03-02 | 东华大学 | Dyeing and finishing wastewater hierarchical treatment process and device |
JP7137696B2 (en) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | Methods and compositions for preventing type 1 diabetes |
TW202140511A (en) * | 2020-01-15 | 2021-11-01 | 瑞士商赫孚孟拉羅股份公司 | Methods to decrease impurities from recombinant protein manufacturing processes |
CN111410688A (en) * | 2020-03-13 | 2020-07-14 | 苏州智享众创孵化管理有限公司 | Separation and purification method for improving purity of bispecific antibody |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US5237054A (en) | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
JPH0565233A (en) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | Monoclonal antibody-containing lyophilized preparation |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
DE4344824C1 (en) | 1993-12-28 | 1995-08-31 | Immuno Ag | Highly concentrated immunoglobulin preparation and process for its preparation |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
ES2251723T3 (en) | 1994-08-12 | 2006-05-01 | Immunomedics, Inc. | SPECIFIC HUMANIZED ANTIBODIES AND ANTIBODIES FOR B-cell LYMPHOMA AND LEUKEMIA CELLS. |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6214221B1 (en) | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
AUPQ599700A0 (en) | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
ES2332402T5 (en) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Concentrated protein formulations of reduced viscosity |
CN1970077A (en) | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | Peptides and related molecules that bind to tall-1 |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
SG173211A1 (en) | 2001-06-26 | 2011-08-29 | Amgen Inc | Antibodies to opgl |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
SI1425389T1 (en) | 2001-08-23 | 2012-02-29 | Genmab As | Human antibodies specific for interleukin 15 (il-15) |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
CN1292655C (en) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | Stable liquid pharmaceutical formulation of IgG antibodies |
US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
ES2449578T3 (en) | 2002-09-06 | 2014-03-20 | Amgen Inc. | Therapeutic human anti-IL-1R1 monoclonal antibody |
AU2003285874A1 (en) | 2002-10-16 | 2004-05-04 | Amgen Inc. | HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
PL2335725T3 (en) | 2003-04-04 | 2017-04-28 | Genentech, Inc. | High concentration antibody and protein formulations |
US7157276B2 (en) | 2003-06-20 | 2007-01-02 | Biogen Idec Inc. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
TWI382031B (en) | 2003-07-15 | 2013-01-11 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
WO2005044854A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
AU2004290017B2 (en) | 2003-11-07 | 2012-05-03 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
WO2007035283A1 (en) | 2005-09-15 | 2007-03-29 | Wyeth | Protein floculation using salts |
WO2008036899A2 (en) * | 2006-09-22 | 2008-03-27 | Amgen Inc. | Methods for removing viral contaminants during protein purification |
EP2089431A4 (en) * | 2006-10-19 | 2010-03-17 | Tolerx Inc | Methods and compositions for efficient removal of protein a from binding molecule preparations |
ES2751022T3 (en) | 2007-07-09 | 2020-03-30 | Genentech Inc | Prevention of reduction of disulfide bonds during recombinant production of polypeptides |
MX350962B (en) | 2008-01-07 | 2017-09-27 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects. |
DE102008037678A1 (en) * | 2008-08-14 | 2010-02-25 | Sartorius Stedim Biotech Gmbh | Depth filter layer with inorganic layer double hydroxide |
CN102257006A (en) | 2008-10-20 | 2011-11-23 | 雅培制药有限公司 | Isolation and purification of antibodies using protein a affinity chromatography |
PT2424889E (en) * | 2009-04-30 | 2015-11-12 | Ablynx Nv | Method for the production of domain antibodies |
WO2011049798A1 (en) | 2009-10-20 | 2011-04-28 | Merck Sharp & Dohme Corp. | Use of mixed mode chromatography for the capture and purification of basic antibody products |
JP5914342B2 (en) | 2009-10-20 | 2016-05-11 | アッヴィ・インコーポレイテッド | Isolation and purification of anti-IL-13 antibody using protein A affinity chromatography |
GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
WO2011140405A1 (en) * | 2010-05-07 | 2011-11-10 | Millipore Corporation | Enhanced clarification media |
JP6039550B2 (en) | 2010-05-18 | 2016-12-07 | アッヴィ・インコーポレイテッド | Protein purification apparatus and method |
AU2011316730B2 (en) * | 2010-10-11 | 2015-12-10 | Abbvie Bahamas Ltd. | Processes for purification of proteins |
AU2011317021B2 (en) * | 2010-10-20 | 2015-07-09 | Medimmune, Llc | Methods for processing inclusion bodies |
US20120238730A1 (en) | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
CN103649297B (en) | 2011-07-08 | 2017-03-01 | Emd密理博公司 | Improvement depth filter for disposable biological technical method |
FR2977893B1 (en) | 2011-07-11 | 2015-02-20 | Lab Francais Du Fractionnement | PROCESS FOR PREPARING A CONCENTRATE OF MULTIPURPOSE IMMUNOGLOBULINS |
PL2739641T5 (en) | 2011-08-02 | 2022-09-05 | Takeda Pharmaceutical Company Limited | Systems and methods to increase protein yield from recombinant manufacturing processes |
WO2013028330A2 (en) * | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
KR102067075B1 (en) | 2011-12-22 | 2020-01-17 | 제넨테크, 인크. | Ion exchange membrane chromatography |
US20140154270A1 (en) | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
US20140010820A1 (en) * | 2012-05-21 | 2014-01-09 | Abbvie, Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
EP2682168A1 (en) * | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
CA2894908C (en) * | 2012-12-20 | 2022-07-12 | Medimmune, Llc | Methods of producing immunoconjugates |
JP2016520655A (en) | 2013-06-04 | 2016-07-14 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | Protein purification process |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
GB201318840D0 (en) | 2013-10-24 | 2013-12-11 | Univ Leeds | Method and device for protein preparation |
US20160272674A1 (en) * | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of antibodies |
KR20160118369A (en) | 2014-02-27 | 2016-10-11 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | Antibody purification process |
EP3119871A4 (en) | 2014-03-17 | 2018-01-03 | Regeneron Pharmaceuticals, Inc. | Clarification of mammalian cell culture |
WO2015198320A1 (en) | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
JP6783767B2 (en) * | 2014-12-22 | 2020-11-11 | アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. | How to Purify Recombinant Protein |
-
2016
- 2016-08-12 HR HRP20231544TT patent/HRP20231544T1/en unknown
- 2016-08-12 FI FIEP16757780.8T patent/FI3334747T3/en active
- 2016-08-12 SG SG10202101105XA patent/SG10202101105XA/en unknown
- 2016-08-12 PT PT167577808T patent/PT3334747T/en unknown
- 2016-08-12 SI SI201631774T patent/SI3334747T1/en unknown
- 2016-08-12 ES ES16757780T patent/ES2964640T3/en active Active
- 2016-08-12 HU HUE16757780A patent/HUE064252T2/en unknown
- 2016-08-12 MA MA042613A patent/MA42613A/en unknown
- 2016-08-12 EP EP22211542.0A patent/EP4209499A1/en active Pending
- 2016-08-12 US US15/751,231 patent/US11098079B2/en active Active
- 2016-08-12 DK DK16757780.8T patent/DK3334747T3/en active
- 2016-08-12 WO PCT/US2016/046929 patent/WO2017027861A1/en active Application Filing
- 2016-08-12 JP JP2018506988A patent/JP6889149B2/en active Active
- 2016-08-12 LT LTEPPCT/US2016/046929T patent/LT3334747T/en unknown
- 2016-08-12 EP EP16757780.8A patent/EP3334747B1/en active Active
- 2016-08-12 PL PL16757780.8T patent/PL3334747T3/en unknown
-
2021
- 2021-07-28 US US17/386,692 patent/US20210363180A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FI3334747T3 (en) | 2023-11-30 |
JP2018526357A (en) | 2018-09-13 |
HUE064252T2 (en) | 2024-02-28 |
SI3334747T1 (en) | 2024-02-29 |
US20180230180A1 (en) | 2018-08-16 |
EP3334747A1 (en) | 2018-06-20 |
PL3334747T3 (en) | 2024-04-02 |
US20210363180A1 (en) | 2021-11-25 |
EP4209499A1 (en) | 2023-07-12 |
US11098079B2 (en) | 2021-08-24 |
DK3334747T3 (en) | 2023-12-11 |
EP3334747B1 (en) | 2023-09-27 |
PT3334747T (en) | 2023-12-12 |
LT3334747T (en) | 2023-12-27 |
HRP20231544T1 (en) | 2024-03-15 |
MA42613A (en) | 2018-06-20 |
ES2964640T3 (en) | 2024-04-08 |
WO2017027861A1 (en) | 2017-02-16 |
JP6889149B2 (en) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285366A (en) | Multispecific antigen-binding proteins | |
HK1253235A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
IL263690A (en) | Purification of multispecific antibodies | |
HK1231400A1 (en) | Selective reduction of proteins | |
IL251125B (en) | Methods of separating gemcitabine-phosphate diastereoisomers | |
SG10202101105XA (en) | Charged depth filtration of antigen-binding proteins | |
IL248697A0 (en) | Methods of purifying antibodies | |
ZA201808524B (en) | Methods of affecting separation | |
GB201904142D0 (en) | Improved method of FT-IMS | |
IL272670A (en) | Preparation of micro-electrodes | |
SG10202007893TA (en) | Methods of immunotherapy | |
IL252712A0 (en) | Method of protein manufacture | |
IL248694B (en) | Nanoencapsulation of antigen-binding molecules | |
HK1223624A1 (en) | Solid forms of tenofovir | |
GB201609314D0 (en) | Methods of forming compounds | |
TWM533475U (en) | Improved structure of filter | |
GB201508443D0 (en) | Methods of identifying USP-binding compounds |